Journal of Medical Biochemistry最新文献

Background: This study aims to evaluate the effectiveness of manual lymphatic drainage (MLD) combined with abdominal breathing in rehabilitating postpartum perineal oedema and Serum IL-6, IL-10, TNF-a.

Methods: A total of 172 primiparous women who delivered in our hospital between January 2022 and June 2023 were randomly assigned to either the observation group (n=86) or the control group (n=86). The control group received routine midwifery care, while the observation group received additional MLD and abdominal breathing training. Outcomes measured included pain levels, induration diameter, comfort, emotional state, recovery time, and clinical efficacy. Inflammatory markers, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumour necrosis factor-alpha (TNF-a), were also assessed.

Results: Both groups demonstrated significant reductions in Self-Rating Anxiety Scale (SAS) and Self-Rating Depression Scale (SDS) scores after treatment (P<0.05), with the observation group showing a greater decrease (P<0.05). The observation group exhibited a significantly shorter recovery time (3.6±1.8 days vs. 4.2±2.5 days, P<0.05) and reported higher comfort levels and lower pain scores than the control group (P<0.05). The effective treatment rate was 97.68% in the observation group, significantly higher than the 82.56% observed in the control group (P<0.05). Inflammatory markers, including IL-6 and TNF-a, showed a significant reduction in the observation group.

Conclusions: Combining MLD and abdominal breathing reduces postpartum perineal oedema effectively, alleviates pain, and enhances recovery. It also lowers inflammatory markers (IL-6, TNF-a) and increases IL-10, promoting faster healing and improved maternal comfort.

Background: This study aimed to compare the effects of Zoledronic Acid (ZA) versus Denosumab (DEN) on bone metabolism, inflammatory response, and immunoglobulins in breast cancer (BC) patients with bone metastases.

Methods: The potential study population consisted of 163 patients with bone metastases BC admitted from May 2023 to June 2024. Through propensity score matching (PSM), 122 patients were included, with 61 patients in the ZA group (treated with ZA) and 61 patients in the DEN group (treated with DEN). Levels of tartrate-resistant acid phosphatase 5b (TRACP-5b), bone glutamyl protein (BGP), bone alkaline phosphatase (BALP), and 25-hydroxyvitamin D3 (25(OH)D3) were measured before and after treatment. Additionally, bone mineral density (BMD) of the lumbar spine (L1-L4) and hip, as well as levels of inflammatory factors and immunoglobulins, were assessed.

Results: After PSM, baseline characteristics were balanced between the ZA and DEN groups (P > 0.05). No significant difference was observed in post-treatment BMD between the two groups (P > 0.05). However, the DEN group showed significantly lower TRACP-5b and BGP levels and notably higher BALP and 25(OH)D3 levels compared to the ZA group (P <0.05). In contrast, the ZA group exhibited lower levels of inflammatory factors and higher immunoglobulin levels than the DEN group (P < 0.05). Regarding safety, a lower incidence of adverse reactions was determined in the DEN group versus the ZA group (P < 0.05).

Conclusions: In the treatment of BC with bone metastases, DEN demonstrated superior benefits for bone metabolism, while ZA showed better regulation of inflammatory response and immune function.

Background: Patients with gastrointestinal tumours often experience malnutrition and compromised immune function during chemotherapy, leading to a significant decline in quality of life. This study aimed to evaluate the effects of dietary nursing interventions on the nutritional status, immune function, and quality of life in patients undergoing chemotherapy.

Methods: A total of 100 patients with gastrointestinal tumours receiving chemotherapy from January 2023 to June 2024 were randomly divided into two groups: a control group (CG) and a study group (SG). Both groups received conventional nursing interventions, but the SG also received dietary nursing interventions focused on personalized nutrition, dietary habits, and gastrointestinal health. Nutritional status was assessed using body mass index (BMI), haemoglobin (HGB), serum albumin (ALB), and oral mucosal cell apoptosis rate. Immune function was evaluated by measuring immunoglobulin M (IgM), immunoglobulin A (IgA), and immunoglobulin G (IgG) levels. Quality of life was measured using the GQOL-74 scale.

Results: After the nursing interventions, the SG showed significant improvements in BMI, HGB, ALB, and oral mucosal cell apoptosis rate compared to the CG (P<0.05). Additionally, IgM, IgA, and IgG levels were significantly higher in the SG (P<0.05). Quality of life scores, including physical, social, psychological, and material life, also improved significantly in the SG compared to the CG (P<0.05).

Conclusions: Dietary nursing interventions significantly improved the nutritional status, immune function, and quality of life of patients with gastrointestinal tumours undergoing chemotherapy. These findings underscore the importance of incorporating dietary care into nursing practices for cancer patients to support their overall well-being and treatment outcomes.

Background: Stroke is a major cause of disability and cognitive deficits, with ischemic stroke (IS) being the most prevalent type, especially in critically ill patients in intensive care units (ICUs). The lactate-to-albumin ratio (LAR) has emerged as a potential predictor of disease outcomes, but its association with shortand long-term mortality in critically ill IS patients is unclear.

Methods: This study analyzed data from 894 critically ill IS patients from the MIMIC-IV database, categorized into LAR tertiles. Clinical endpoints included ICU, hospital, and 30and 90-day all-cause mortality. Survival differences were assessed using Kaplan-Meier analysis. Cox proportional-hazards regression models and restricted cubic spline (RCS) analysis evaluated the association between LAR and mortality outcomes. Subgroup analyses examined the modifying effects of clinical characteristics on LAR's predictive value.

Results: The ICU, hospital, 30-, and 90-day mortality rates were 15.0%, 22.3%, 28.2%, and 36.1%, respectively. Higher LAR levels were associated with reduced survival times and increased mortality risks in all endpoints. Multivariable Cox models confirmed LAR as an independent predictor of 30and 90-day mortality. RCS analysis indicated a linear relationship between LAR and ICU mortality (P = 0.109), and a non-linear association with hospital (P = 0.005), 30-day (P < 0.001), and 90-day mortality (P < 0.001). Subgroup analyses highlighted significant interactions for respiratory failure and GCS.

Conclusions: LAR is a robust predictor of shortand longterm mortality in critically ill IS patients, offering clinicians a valuable tool for risk stratification and decision-making.

Background: The objective of this study was to investigate the biochemical impact of laparoscopic surgery on angiogenesis, focusing on vascular endothelial growth factor (VEGF), and the modulation of key tumor markers in patients with early-stage ovarian cancer.

Methods: A total of 76 patients diagnosed with early ovarian cancer were enrolled and divided into two groups based on the surgical approach: the control group (n=38) underwent open surgery, and the observation group (n=38) underwent laparoscopic surgery. Surgical parameters, VEGF levels, tumor markers [matrix metalloproteinase 9 (MMP9), stromal cell-derived factor-1a (SDF-1a), and carcinoembryonic antigen (CEA)], survival rates, and incidence of complications were compared between the two groups.

Results: The duration of surgery was longer in the observation group than in the control group. However, the hospitalization time, recovery of bowel function, and length of surgical incision were significantly shorter in the observation group. Intraoperative blood loss was also significantly lower in the observation group, with all differences being statistically significant (P<0.01). Seven days post-surgery, VEGF, MMP9, SDF-1a, and CEA levels in both groups decreased compared to their preoperative levels. These levels were significantly lower in the observation group than in the control group (P<0.05). The 24-month survival rate was higher in the observation group (P<0.05). There was no statistically significant difference in the total incidence of complications between the two groups (P>0.05).

Conclusions: Laparoscopic surgery for early ovarian cancer results in minimal trauma, reduces VEGF and tumor marker levels, and improves the 24-month survival rate without increasing the incidence of complications.

Background: Patients with psoriasis are at an increased risk of cardiovascular disease (CVD). Psoriasis and atherosclerosis share the common soil of inflammation and oxidative stress in their pathogenesis. The current study aimed to examine cardiovascular risk concerning some non-traditional (i.e., biomarkers of oxidative stress and inflammation) and traditional metabolic parameters in patients with psoriasis.

Methods: A total of 68 (57% men) patients with psoriasis were included. Traditional metabolic parameters, markers of oxidative stress[i.e., oxidation protein products (AOPP), malondialdehyde (MDA), catalase (CAT), and superoxide dismutase (SOD)] and inflammation (C-reactive protein) were measured. The atherosclerotic cardiovascular disease (ASCVD) risk score was used to measure CVD risk. Patients were divided into ASCVD score tertiles.

Results: Patients with a higher ASCVD score had significantly lower high-density lipoprotein cholesterol (HDL-C), higher triglycerides (TG), and higher TG/HDL-C ratio (p for trend p<0.001). Among redox status parameters, only AOPP showed a significant increase in parallel with the ASCVD score increase (p=0.011). In univariate binary logistic regression analysis, AOPP [OR, 95% CI=1.027 (1.004-1.051), p=0.021] and TG [OR, 95% CI =7.220 (2.041-25.548), p=0.002] correlated with the ASCVD risk score. In multivariate analysis (backward method), only TG was an independent predictor of ASCVD score [OR, 95%CI =7.220 (2.041-25.548), p=0.002].

Conclusions: The results show the association between ASCVD score and oxidative stress (AOPP) and dyslipidemia (TG), respectively, in patients with psoriasis, but only TG retained its independent association with ASCVD risk score. Measuring serum TG levels is very important in patients with increased ASCVD risk concerning psoriasis.

Background: Postmenopausal osteoporosis (PMOP) is a prevalent metabolic bone disorder characterized by decreased bone mineral density (BMD) and skeletal fragility, leading to increased susceptibility to fractures. The therapeutic efficacy of zoledronic acid and denosumab, two widely used agents in the treatment of osteoporosis, was investigated in this study. The primary objective was to evaluate the clinical effects of zoledronic acid and denosumab on serum inflammatory cytokine (IFC) levels and BMD in PMOP patients.

Methods: A prospective, non-blinded, randomized controlled trial was conducted at our hospital from March 2021 to March 2024. Eighty PMOP patients were recruited and randomly assigned to either a control group (CG, n=40) or a treatment group (TG, n=40). The CG received zoledronic acid plus traditional treatment, while the TG received zoledronic acid plus denosumab plus traditional treatment. Clinical symptom improvement and changes in BMD were assessed and compared between the two groups. Serum IFC levels, including bone Gla protein (BGP) and bone turnover markers b-collagen degradation product (b-CTX) and procollagen type 1 N-terminal propeptide (P1NP), were measured.

Results: Compared to the CG, patients in the TG demonstrated significantly increased BMD (P<0.05) and decreased levels of serum IFCs, BGP, and bone turnover markers (P<0.05). Additionally, the incidence of adverse reactions was significantly lower (P<0.05) in the TG, and the total effective rate of clinical treatment was significantly higher (P<0.05).

Conclusions: The combination of zoledronic acid and denosumab exhibited improved clinical efficacy in PMOP patients, as evidenced by enhanced BMD and reduced serum IFC levels. These findings suggest that this combined treatment regimen may promote the treatment of osteoporosis by suppressing inflammatory responses, thereby providing a novel therapeutic approach for the management of PMOP.

Background: This study focuses on uncovering the effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in attenuating arterial stiffness in patients with acute coronary syndrome (ACS) and atherosclerosis.

Methods: A total of 71 ACS patients were enrolled in this study from April 1, 2022, to June 31, 2022. Patients were randomly assigned to two groups: one group received statin therapy combined with PCSK9 inhibitors (Evolocumab 140 mg or Alirocumab 75 mg every two weeks) (n = 36), and the other group received statins alone (n = 35). All patients underwent measurements of lipid metabolism and arterial stiffness at baseline, 1 month, and 6 months after treatment initiation. Statistical power analysis indicated that the sample size of 71 patients provided sufficient power to detect significant differences.

Results: After 1 month, the group treated with statins and PCSK9 inhibitors showed significantly greater reductions in total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL), and lipoprotein(a) [Lp(a)] levels compared to the statin-only group (p = 0.027 and p = 0.021, respectively). By the 6-month follow-up, significant reductions were observed in pulse wave velocity (PWV) and ankle-brachial index (ABI) in the combination treatment group (p < 0.05). However, no significant differences were observed between Evolocumab and Alirocumab in terms of arterial stiffness improvement (p > 0.05). Statistical power was sufficient to detect these changes.

Conclusions: The findings suggest that PCSK9 inhibitors, when combined with statins, not only improve lipid metabolism but also reduce arterial stiffness, offering potential benefits for vascular health in patients with ACS and atherosclerosis. Further studies with larger sample sizes and longer follow-up periods are necessary to confirm these results.

Background: Adverse reactions (ARs) may occur in patients with advanced non-small cell lung cancer (ANSCLC) undergoing treatment with programmed cell death protein 1 (PD-1) inhibitors (PD-1Is). Establishing a risk assessment model can facilitate personalized treatment.

Methods: Clinical data were collected from 215 ANSCLC patients treated with PD-1Is. Patients who experienced ARs were classified as the observation group (OG, 92 cases), while those who did not experience ARs were classified as the control group (CG, 123 cases). A multivariable logistic regression (LR) model was employed to analyze independent risk factors (RFs) associated with ARs, and R Studio software was utilized to create a nomogram predictive model.

Results: The concordance index for the nomogram predictive model for ARs in ANSCLC patients treated with PD-1Is was 0.911. The threshold for predicting ARs using the nomogram was more significant than 0.25, providing a clinical net benefit superior to individual indicators such as smoking, tumour-node-metastasis (TNM) staging, neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI). The proportion of smokers in the OG was markedly superior to that in the CG (P<0.05).

Conclusions: Smoking, TNM staging, and peripheral blood indicators such as NLR, SII, and PNI are independent RFs for the occurrence of ARs. The constructed nomogram predictive model demonstrates greater clinical utility than individual indicators, enhancing the accuracy of AR predictions.

Background: To evaluate the impact of traditional Chinese medicine treatment versus standard treatment on cardiac function metrics, serum inflammatory markers, and quality of life in patients with chronic heart failure (CHF).

Methods: A total of 40 CHF patients were randomly assigned to either the observation group (TCM treatment) or the control group (standard Western therapy), with 20 patients in each group. Over a 3-month treatment period, primary outcomes including cardiac function indicators (ejection fraction [EF], cardiac output [CO], left ventricular end-diastolic pressure [LVEDP]), exercise tolerance (6-minute walk test [6MWT] results), and inflammatory markers (high-sensitivity C-reactive protein [hs-CRP], interleukin-6 [IL-6], tumor necrosis factor-alpha [TNF-a]) were assessed. Secondary outcomes included the Minnesota Living with Heart Failure Questionnaire (MLHFQ) scores and adverse reaction rates. Statistical analysis was performed using t-tests and chi-square tests, with significance set at P < 0.05.

Results: After treatment, the observation group showed significantly greater improvements in EF (44.14% ± 4.95% vs. 40.15% ± 4.77%, P = 0.013), CO (4.62 ± 0.76 L/min vs. 4.10 ± 0.72 L/min, P = 0.032), LVEDP (18.76 ± 2.50 mmHg vs. 20.80 ± 2.64 mmHg, P = 0.016), and 6MWT results (526.84 ± 49.20 m vs. 432.75 ± 37.26 m, P < 0.001), compared to the control group. Inflammatory markers and MLHFQ scores were also significantly improved, while the adverse reaction rate was lower in the observation group (0.00% vs. 20.00%, P = 0.035).

Conclusions: TCM as an adjunctive therapy demonstrates superior efficacy and safety compared to standard treatment for CHF, with significant improvements in cardiac function, exercise tolerance, and inflammatory markers. These findings provide quantitative evidence supporting the clinical application of TCM in CHF management.